Decrease in Heart Rate Below Baseline Value
Conditions
Keywords
heart rate
Brief summary
Beta 1 Adrenergic antagonists (beta blockers) have major role in the treatment of CHF, IHD and hypertension. However, there is large interindividual variability in the response to beta blockers. The hypothesis underlying this study is that genetic differences between individuals will determine the individual response to esmolol, a betablocker that is administered intravenously. Esmolol will be administered intravenously to healthy volunteers, and the effects on heart rate and blood pressure will be monitored. In addition, we will measure plasma renin activity and plasma levels of norepinephrine.
Interventions
DRUGesmolol
consecutive infusions of esmolol and normal saline (placebo)
Sponsors
Hadassah Medical Organization
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* healthy male and female * able to understand and sign informed consent
Exclusion criteria
* consumption of any medication * bradycardia \<50 BPM * hypersensitivity to beta blockers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in heart rate during exercise | 3 hours | continous measurement of heart rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change in systolic blood pressure during exercise | 3 hours | measurement of systolic blood pressure every 5 minutes |
Countries
Israel
Contacts
Primary ContactMordechai Muszkat, MD
Outcome results
None listed